VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time to discuss their third quarter 2024 financial and operating results, along with a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera, and Dr. Andrew Retter. A live audio webcast will be available, and a telephone replay will be accessible until November 29, 2024.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VNRX gained 5.44%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time
Event: VolitionRx Limited Third Quarter 2024 Earnings and Business Update Conference Call
Date: Friday, November 15, 2024
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13750104
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the third quarter of 2024 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until November 29, 2024. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish,
Volition,
mediarelations@volition.com,
+44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-third-quarter-2024-earnings-conference-call-and-business-update-302299871.html
SOURCE VolitionRx Limited